Arvinas Inc
Veridion Score
BETAHIGH CONF · 6/6 factorsComposite intelligence score across six company factor categories. Missing inputs are excluded from the active factor subset.
- · Factor breakdown with raw signals
- · Day-over-day delta + driver
- · Factor coverage readout
- · Valuation · hype · market flow
- · Pro Chart event markers
- · Score history + alerts
Why is ARVN moving today?
Arvinas Inc is a clinical-stage biotechnology company focused on improving the lives of patients suffering from debilitating and life-threatening diseases through the discovery, development, and commercialization of therapies that degrade disease-causing proteins. The company is using its PROteolysis TArgeting Chimera, a protein degradation platform, to develop therapeutics designed to harness the body's own natural protein disposal system to selectively and efficiently degrade and remove disease-causing proteins. Its clinical development program includes various product candidates such as ARV-102, ARV-806, ARV-393, ARV-027, and vepdegestrant, in their different stages of development, being developed to target certain harmful proteins causing oncology and neurology-related diseases.
Reported fields plus Veridion-computed history. Unsourced tiles are omitted.
ARVN overview
Related filings and maps
Congress activity in ARVN
No receipt-qualified Congressional disclosure is present for ARVN in the cached public ledger.
ARVN contract awards, year to date.
Public federal awards linked to this ticker.
ARVN lobbying filings, year to date.
Registered lobbying filings matched to Arvinas Inc.